JP2019501134A5 - - Google Patents

Info

Publication number

JP2019501134A5

JP2019501134A5 JP2018526717A JP2018526717A JP2019501134A5 JP 2019501134 A5 JP2019501134 A5 JP 2019501134A5 JP 2018526717 A JP2018526717 A JP 2018526717A JP 2018526717 A JP2018526717 A JP 2018526717A JP 2019501134 A5 JP2019501134 A5 JP 2019501134A5

Authority

JP

Japan

Prior art keywords

methoxy

pyrrolidin

acetamide

amino

thiadiazol

Prior art date

2016-11-30

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims 13
• 150000003839 salts Chemical class 0.000 claims 11
• -1 5-methylpyridazin-3-yl Chemical group 0.000 claims 10
• 239000003814 drug Substances 0.000 claims 5
• 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
• 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 4
• 229910052739 hydrogen Inorganic materials 0.000 claims 4
• 239000001257 hydrogen Substances 0.000 claims 4
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
• 239000008194 pharmaceutical composition Substances 0.000 claims 4
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
• 201000010099 disease Diseases 0.000 claims 3
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
• 230000001404 mediated effect Effects 0.000 claims 3
• QFAHGXFMNKFWKL-KDOFPFPSSA-N (2S)-2-(4-fluoro-3-methoxyphenyl)-2-methoxy-N-[5-[[(3R)-1-(6-methylpyridazin-3-yl)pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide Chemical compound FC1=C(C=C(C=C1)[C@@H](C(=O)NC=1SC(=NN=1)N[C@H]1CN(CC1)C=1N=NC(=CC=1)C)OC)OC QFAHGXFMNKFWKL-KDOFPFPSSA-N 0.000 claims 2
• NKPBNEQDGYAJFW-WBVHZDCISA-N (2S)-2-(4-fluorophenyl)-2-methoxy-N-[5-[[(3R)-1-(5-methylpyridazin-3-yl)pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide Chemical compound FC1=CC=C(C=C1)[C@@H](C(=O)NC=1SC(=NN=1)N[C@H]1CN(CC1)C=1N=NC=C(C=1)C)OC NKPBNEQDGYAJFW-WBVHZDCISA-N 0.000 claims 2
• HXFKMUYISOOFNN-WBVHZDCISA-N (2S)-2-(4-fluorophenyl)-2-methoxy-N-[5-[[(3R)-1-(6-methylpyridazin-3-yl)pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide Chemical compound FC1=CC=C(C=C1)[C@@H](C(=O)NC=1SC(=NN=1)N[C@H]1CN(CC1)C=1N=NC(=CC=1)C)OC HXFKMUYISOOFNN-WBVHZDCISA-N 0.000 claims 2
• PWHLVMVNBKXNML-APWZRJJASA-N (2S)-2-ethoxy-2-(3-methoxyphenyl)-N-[5-[[(3R)-1-(6-methylpyridazin-3-yl)pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide Chemical compound C(C)O[C@H](C(=O)NC=1SC(=NN=1)N[C@H]1CN(CC1)C=1N=NC(=CC=1)C)C1=CC(=CC=C1)OC PWHLVMVNBKXNML-APWZRJJASA-N 0.000 claims 2
• CJPDRLNNFXCJTE-QAPCUYQASA-N (2S)-2-methoxy-2-(3-methoxyphenyl)-N-[5-[[(3R)-1-(6-methylpyridazin-3-yl)pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide Chemical compound CO[C@H](C(=O)NC=1SC(=NN=1)N[C@H]1CN(CC1)C=1N=NC(=CC=1)C)C1=CC(=CC=C1)OC CJPDRLNNFXCJTE-QAPCUYQASA-N 0.000 claims 2
• SKUZHMFUXHGQQW-DYVFJYSZSA-N (2S)-N-[5-[[(3R)-1-(6-fluoropyridazin-3-yl)pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]-2-methoxy-2-(3-methoxyphenyl)acetamide Chemical compound FC1=CC=C(N=N1)N1C[C@@H](CC1)NC1=NN=C(S1)NC([C@H](C1=CC(=CC=C1)OC)OC)=O SKUZHMFUXHGQQW-DYVFJYSZSA-N 0.000 claims 2
• 206010028980 Neoplasm Diseases 0.000 claims 2
• 201000011510 cancer Diseases 0.000 claims 2
• 125000001153 fluoro group Chemical group F* 0.000 claims 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
• BILNGVPSJLOCKW-CJNGLKHVSA-N (2S)-N-[5-[[(3R)-1-(6-fluoropyridazin-3-yl)pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]-2-methoxy-2-phenylacetamide Chemical compound FC1=CC=C(N=N1)N1C[C@@H](CC1)NC1=NN=C(S1)NC([C@H](C1=CC=CC=C1)OC)=O BILNGVPSJLOCKW-CJNGLKHVSA-N 0.000 claims 1
• 206010006187 Breast cancer Diseases 0.000 claims 1
• 208000026310 Breast neoplasm Diseases 0.000 claims 1
• 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
• FURBCBVZJOABRQ-XPCCGILXSA-N N-[5-[[(3R)-1-(5-chloropyridazin-3-yl)pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]-2-methoxy-2-(4-methoxyphenyl)acetamide Chemical compound ClC=1C=C(N=NC=1)N1C[C@@H](CC1)NC1=NN=C(S1)NC(C(C1=CC=C(C=C1)OC)OC)=O FURBCBVZJOABRQ-XPCCGILXSA-N 0.000 claims 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
• 206010038389 Renal cancer Diseases 0.000 claims 1
• 239000003085 diluting agent Substances 0.000 claims 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
• 201000010982 kidney cancer Diseases 0.000 claims 1
• 201000005202 lung cancer Diseases 0.000 claims 1
• 208000020816 lung neoplasm Diseases 0.000 claims 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
• 201000002528 pancreatic cancer Diseases 0.000 claims 1
• 208000008443 pancreatic carcinoma Diseases 0.000 claims 1